Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China

References

• Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. 2020;42(1):1–9. doi: 10.1007/s00281-020-00785-1.
   PubMed Web of Science ®Google Scholar
• García-Marcos L, Asher MI, Pearce N, et al. The burden of asthma, hay fever and eczema in children in 25 countries: GAN phase I study. Eur Respir J. 2022;60(3):2102866. doi: 10.1183/13993003.02866-2021.
   PubMed Web of Science ®Google Scholar
• Deng Z, Jin M, Ou C, et al. Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies. Chin Med J. 2023;136(2):230–232. doi: 10.1097/CM9.0000000000002556.
   PubMed Web of Science ®Google Scholar
• Pavord I, Bahmer T, Braido F, et al. Severe T2-high asthma in the biologics era: european experts’ opinion. Eur Respir Rev. 2019;28(152):190054. doi: 10.1183/16000617.0054-2019.
   PubMed Web of Science ®Google Scholar
• Guilleminault L, Conde E, Reber LL. Pharmacological approaches to target type 2 cytokines in asthma. Pharmacol Ther. 2022;237:108167. doi: 10.1016/j.pharmthera.2022.108167.
   PubMed Web of Science ®Google Scholar
• P C, H E, C C, et al. Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets. Front Pharmacol. 2022;13:851940. [cited 2024 Jan 7]. https://pubmed.ncbi.nlm.nih.gov/35350765/.
   Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi: 10.1016/S0140-6736(19)31881-1.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi: 10.1056/NEJMoa1804092.
   PubMed Web of Science ®Google Scholar
• Chong LY, Piromchai P, Sharp S, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021;3(3):CD013513.
   PubMedGoogle Scholar
• P C, B A, B M, et al. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps. Front Immunol. 2023;14:1121237.
   Google Scholar
• Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090–1091.
   PubMedGoogle Scholar
• Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34(2):e74–e76. doi: 10.1111/jdv.15957.
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122.e10. doi: 10.1053/j.gastro.2019.09.042.
   PubMed Web of Science ®Google Scholar
• Rabe KF, FitzGerald JM, Bateman ED, et al. Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-Defined type 2 asthma irrespective of an allergic asthma phenotype. J Allergy Clin Immunol Pract. 2022;10(11):2916–2924.e4. doi: 10.1016/j.jaip.2022.06.036.
   PubMed Web of Science ®Google Scholar
• Olaguibel JM, Sastre J, Rodríguez JM, et al. Eosinophilia induced by blocking the IL-4/IL-13 pathway: potential mechanisms and clinical outcomes. J Investig Allergol Clin Immunol. 2022;32(3):165–180. doi: 10.18176/jiaci.0823.
   PubMed Web of Science ®Google Scholar
• Menzella F, Montanari G, Patricelli G, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag. 2019;15:869–875. doi: 10.2147/TCRM.S207402.
   PubMed Web of Science ®Google Scholar
• Suzaki I, Tanaka A, Yanai R, et al. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report. BMC Pulm Med. 2023;23(1):130. doi: 10.1186/s12890-023-02415-6.
   PubMed Web of Science ®Google Scholar
• Kai Y, Yoshikawa M, Matsuda M, et al. Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: a case report. Respir Med Case Rep. 2022;39:101723. doi: 10.1016/j.rmcr.2022.101723.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466. doi: 10.1056/NEJMoa1304048.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL-1. Eur Respir J. 2022;59(6):2102577. doi: 10.1183/13993003.02577-2021.
   PubMed Web of Science ®Google Scholar
• Tosuji E, Inaba Y, Muraoka K, et al. The clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis. Drug Discov Ther. 2022;16(4):164–168. doi: 10.5582/ddt.2022.01046.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Angileri L, Tavecchio S, et al. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease. J Dermatolog Treat. 2022;33(5):2587–2592. doi: 10.1080/09546634.2022.2049588.
   PubMed Web of Science ®Google Scholar
• Wechsler M, Klion A, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. https://pubmed.ncbi.nlm.nih.gov/35636689/
   PubMed Web of Science ®Google Scholar
• Caminati M, Olivieri B, Dama A, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med. 2022;16(7):713–721. doi: 10.1080/17476348.2022.2090342.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi: 10.1056/NEJMoa1804093.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1.
   PubMed Web of Science ®Google Scholar
• Iino Y, Sekine Y, Yoshida S, et al. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma. Auris Nasus Larynx. 2021;48(3):353–360. doi: 10.1016/j.anl.2020.09.001.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Hayashi M, Kato H, et al. IL13 may play an important role in developing eosinophilic chronic rhinosinusitis and eosinophilic otitis media with severe asthma. Int J Mol Sci. 2021;22(20):11209. doi: 10.3390/ijms222011209.
   PubMed Web of Science ®Google Scholar